Blockade of immune checkpoints, including the cytotoxic T lymphocyte-associated protein (CTLA)-4 and the programmed cell death-1 (PD-1)/PD ligand-1 (PD-L1) pathway, have increased overall survival and progression-free survival of cancer patients. Here, PDCD1 is linked to cancer.